Abstract：
It has been established that translationally controlled tumor protein (TCTP), also called histamine releasing factor (HRF), exhibits cytokine-like activities associated with initiation of allergic responses only after forming dimers (dTCTP). Agents that inhibit dTCTP by preventing its dimerization or otherwise block its function, also block development of allergic reactions, thereby serving as potential drugs to treat allergic diseases. Several lines of evidence have proven that peptides and antibodies that specifically inhibit the interactions between dTCTP and either its putative receptor or immunoglobulins exhibit significant in vivo efficacy as potential anti-inflammatory agents in murine models of allergic inflammatory diseases. This review highlights the development of several inhibitors targeting dTCTP and discusses how they affect the pathophysiological processes of allergic and inflammatory diseases in several animal models and offers new perspectives on anti-allergic drug discovery.
摘要：
已经确定翻译控制肿瘤蛋白（TCTP），也称为组胺释放因子（HRF），仅在形成二聚体（dTCTP）后才表现出与过敏反应启动相关的细胞因子样活性。通过阻止dTCTP的二聚化或以其他方式阻断其功能来抑制dTCTP的药物，也阻止过敏反应的发展，从而作为治疗过敏性疾病的潜在药物。若干证据已经证明,特异性抑制dTCTP与其推定受体或免疫球蛋白之间的相互作用的肽和抗体在过敏性炎性疾病的鼠模型中作为潜在的抗炎剂表现出显著的体内功效。这篇综述重点介绍了几种针对dTCTP的抑制剂的开发，并讨论了它们如何在几种动物模型中影响过敏性和炎症性疾病的病理生理过程，并为抗过敏药物的发现提供了新的视角。
